A few years later

References

• Rozenbaum MH, Sanders EAM, van Hoek AJ, Jansen AGSC, van der Ende A, van den Dobbelsteen G, Rodenburg GD, Hak E, Postma MJ. Cost effectiveness of pneumococcal vaccination among Dutch infants: economic analysis of the seven valent pneumococcal conjugated vaccine and forecast for the 10 valent and 13 valent vaccines. BMJ 2010; 340:c2509 c2509; http://dx.doi.org/10.1136/bmj.c2509; PMID: 20519267
   PubMed Web of Science ®Google Scholar
• Rozenbaum MH, Hoek AJ, Hak E, Postma MJ. Huge impact of assumptions on indirect effects on the cost-effectiveness of routine infant vaccination with 7-valent conjugate vaccine (Prevnar). Vaccine 2010; 28:2367 - 9; http://dx.doi.org/10.1016/j.vaccine.2010.01.005; PMID: 20085833
   PubMed Web of Science ®Google Scholar
• Health Council of the Netherlands. Vaccinatie tegen pneumokokken [in Dutch “Vaccination of infants against pneumococcal infections”]. 2010;2010/02(2005/13).
   Google Scholar
• Casey JR, Adlowitz DG, Pichichero ME. New patterns in the otopathogens causing acute otitis media six to eight years after introduction of pneumococcal conjugate vaccine. Pediatr Infect Dis J 2010; 29:304 - 9; PMID: 19935445
   PubMed Web of Science ®Google Scholar
• Rodenburg GD, de Greeff SC, Jansen AG, de Melker HE, Schouls LM, Hak E, Spanjaard L, Sanders EA, van der Ende A. Effects of pneumococcal conjugate vaccine 2 years after its introduction, the Netherlands. Emerg Infect Dis 2010; 16:816 - 23; http://dx.doi.org/10.3201/eid1605.091223; PMID: 20409372
   PubMed Web of Science ®Google Scholar
• Miller E, Andrews NJ, Waight PA, Slack MP, George RC. Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study. Lancet Infect Dis 2011; 11:760 - 8; http://dx.doi.org/10.1016/S1473-3099(11)70090-1; PMID: 21621466
   PubMed Web of Science ®Google Scholar
• Cohen R, Levy C, Bingen E, Bechet S, Derkx V, Werner A, Koskas M, Varon E. [Nasopharyngeal carriage of children 6 to 60 months during the implementation of the 13-valent pneumococcal conjugate vaccine]. Arch Pediatr 2012; 19:1132 - 9; http://dx.doi.org/10.1016/j.arcped.2012.07.013; PMID: 22925540
   PubMed Web of Science ®Google Scholar
• van Deursen AM, van Mens SP, Sanders EA, Vlaminckx BJ, de Melker HE, Schouls LM, de Greeff SC, van der Ende A, Invasive Pneumococcal Disease Sentinel Surveillance Laboratory Group. Invasive pneumococcal disease and 7-valent pneumococcal conjugate vaccine, the Netherlands. Emerg Infect Dis 2012; 18:1729 - 37; http://dx.doi.org/10.3201/eid1811.120329; PMID: 23092683
   PubMed Web of Science ®Google Scholar
• De Wals P, Lefebvre B, Defay F, Deceuninck G, Boulianne N. Invasive pneumococcal diseases in birth cohorts vaccinated with PCV-7 and/or PHiD-CV in the province of Quebec, Canada. Vaccine 2012; 30:6416 - 20; http://dx.doi.org/10.1016/j.vaccine.2012.08.017; PMID: 22921290
   PubMed Web of Science ®Google Scholar
• Kaplan SL, Barson WJ, Lin PL, Romero JR, Bradley JS, Tan TQ, Hoffman JA, Givner LB, Mason EO Jr.. Early trends for invasive pneumococcal infections in children after the introduction of the 13-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J 2013; 32:203 - 7; http://dx.doi.org/10.1097/INF.0b013e318275614b; PMID: 23558320
   PubMed Web of Science ®Google Scholar
• Effectiveness of the 10-valent pneumococcal Haemophilus Influenzae Protein D COnjugate Vaccines (PHiD-CV10) against hospital-diagnosed pneumonia in infants - FINIP trial . 31st Meeting of the European Society for Paediatric Infectious Diseases (ESPID 2013) ; May 2013; ; 2013.
   Google Scholar
• Palmu AA, Jokinen J, Borys D, Nieminen H, Ruokokoski E, Siira L, Puumalainen T, Lommel P, Hezareh M, Moreira M, et al. Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against invasive pneumococcal disease: a cluster randomised trial. Lancet 2013; 381:214 - 22; http://dx.doi.org/10.1016/S0140-6736(12)61854-6; PMID: 23158882
   PubMed Web of Science ®Google Scholar
• Efficacy of 10-valent pneumococcal non-typeable Haemophilus influenzae Protein D conjugate vaccine (PHiD-CV) against acute otitis media in children in Panama. . 9th International Symposium onAntimicrobial Agents and Resistance (ISAAR 2013); March 2013; ; 2013.
   Google Scholar
• TenderNed. Aankondiging van een opdracht:Pneumococcal Vaccine -Rijksinstituut voor Volksgezondheid en Milieu (RIVM) [Contract notice: Pneumococcal Vaccine -Institute for Public Health and the Environment (RIVM)]. 2014; Available at: https://www.tenderned.nl/tenderned-web/aankondiging/detail/samenvatting/akid/f52bf20f62d2535a8d402a6492e72777. Accessed 02/17, 2014.
   Google Scholar
• Wie wordt er ziek en van welke pneumokok? [Who gets sick and from which pneumococcal serotype?]. Symposium Vaccinonderzoek in Nederland; Het Laatste Nieuws; 2013.
   Google Scholar
• Prymula R, Peeters P, Chrobok V, Kriz P, Novakova E, Kaliskova E, Kohl I, Lommel P, Poolman J, Prieels JP, et al. Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: a randomised double-blind efficacy study. Lancet 2006; 367:740 - 8; http://dx.doi.org/10.1016/S0140-6736(06)68304-9; PMID: 16517274
   PubMed Web of Science ®Google Scholar
• De Wals P, Erickson L, Poirier B, Pépin J, Pichichero ME. How to compare the efficacy of conjugate vaccines to prevent acute otitis media?. Vaccine 2009; 27:2877 - 83; http://dx.doi.org/10.1016/j.vaccine.2009.02.102; PMID: 19366579
   PubMed Web of Science ®Google Scholar
• Gezondheidsraad. Vaccinatie van zuigelingen tegen pneumokokkeninfecties (3). [Vaccination of infants against pneumococcal infections (3)]. 2013;2013/28.
   Google Scholar
• van den Bergh MR, Spijkerman J, Swinnen KM, François NA, Pascal TG, Borys D, Schuerman L, Ijzerman EP, Bruin JP, van der Ende A, et al. Effects of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D-conjugate vaccine on nasopharyngeal bacterial colonization in young children: a randomized controlled trial. Clin Infect Dis 2013; 56:e30 - 9; http://dx.doi.org/10.1093/cid/cis922; PMID: 23118268
   PubMed Web of Science ®Google Scholar
• College voor Zorgverzekeringen. Richtlijnen voor farmaco-economisch onderzoek; evaluatie en actualisatie [Guidelines for pharmacoeconomic research: evaluation and actualization]. 2008.
   Google Scholar
• Statistics Netherlands. CBS Statline. 2013; Available at: http://statline.cbs.nl/statweb/. Accessed 05/14, 2013.
   Google Scholar
• Medicijnkosten CVZ. 2013; Available at: www.medicijnkosten.nl. Accessed 05/17, 2013.
   Google Scholar
• Black S, Shinefield H, Fireman B, Lewis E, Ray P, Hansen JR, Elvin L, Ensor KM, Hackell J, Siber G, et al, Northern California Kaiser Permanente Vaccine Study Center Group. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Pediatr Infect Dis J 2000; 19:187 - 95; http://dx.doi.org/10.1097/00006454-200003000-00003; PMID: 10749457
   PubMed Web of Science ®Google Scholar
• Black SB, Shinefield HR, Ling S, Hansen J, Fireman B, Spring D, Noyes J, Lewis E, Ray P, Lee J, et al. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia. Pediatr Infect Dis J 2002; 21:810 - 5; http://dx.doi.org/10.1097/00006454-200209000-00005; PMID: 12352800
   PubMed Web of Science ®Google Scholar
• Eskola J, Kilpi T, Palmu A, Jokinen J, Haapakoski J, Herva E, Takala A, Käyhty H, Karma P, Kohberger R, et al, Finnish Otitis Media Study Group. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med 2001; 344:403 - 9; http://dx.doi.org/10.1056/NEJM200102083440602; PMID: 11172176
   PubMed Web of Science ®Google Scholar
• Dagan R, Patterson S, Juergens C, Greenberg D, Givon-Lavi N, Porat N, Gurtman A, Gruber WC, Scott DA. Comparative immunogenicity and efficacy of 13-valent and 7-valent pneumococcal conjugate vaccines in reducing nasopharyngeal colonization: a randomized double-blind trial. Clin Infect Dis 2013; 57:952 - 62; http://dx.doi.org/10.1093/cid/cit428; PMID: 23804191
   PubMed Web of Science ®Google Scholar
• Lucero MG, Dulalia VE, Nillos LT, Williams G, Parreno RA, Nohynek H, et al. Pneumococcal conjugate vaccines for preventing vaccine-type invasive pneumococcal disease and X-ray defined pneumonia in children less than two years of age. Cochrane Database Syst Rev. 2009 Oct 7;(4):CD004977
   Google Scholar
• Van Lier EA, Oomen PJ, Oostenbrug MWM, Zwakhals SLN, Drijfhout IH, De Hoogh PAAM, et al. Vaccinatiegraad Rijksvaccinatieprogramma Nederland. Verslagjaar 2009 [In Dutch: “Vaccination level in the Dutch National Immunization Program. Ned Tijdschr Geneeskd. 2009 May 16;153(20):950-7
   Google Scholar
• Jansen AG, Rodenburg GD, de Greeff SC, Hak E, Veenhoven RH, Spanjaard L, Schouls LM, Sanders EA, van der Ende A. Invasive pneumococcal disease in the Netherlands: Syndromes, outcome and potential vaccine benefits. Vaccine 2009; 27:2394 - 401; http://dx.doi.org/10.1016/j.vaccine.2009.01.127; PMID: 19428856
   PubMed Web of Science ®Google Scholar
• Hubben GA, Bos JM, Glynn DM, van der Ende A, van Alphen L, Postma MJ. Enhanced decision support for policy makers using a web interface to health-economic models--illustrated with a cost-effectiveness analysis of nation-wide infant vaccination with the 7-valent pneumococcal conjugate vaccine in the Netherlands. Vaccine 2007; 25:3669 - 78; http://dx.doi.org/10.1016/j.vaccine.2007.01.088; PMID: 17360082
   PubMed Web of Science ®Google Scholar
• Oostenbrink R, A Moll HA, Essink-Bot ML. The EQ-5D and the Health Utilities Index for permanent sequelae after meningitis: a head-to-head comparison. J Clin Epidemiol 2002; 55:791 - 9; http://dx.doi.org/10.1016/S0895-4356(02)00448-1; PMID: 12384194
   PubMed Web of Science ®Google Scholar
• WHO. Global burden of disease 2004 update: disability weights for diseases and conditions. 2004.
   Google Scholar
• Krabbe PF, Hinderink JB, van den Broek P. The effect of cochlear implant use in postlingually deaf adults. Int J Technol Assess Health Care 2000; 16:864 - 73; http://dx.doi.org/10.1017/S0266462300102132; PMID: 11028141
   PubMed Web of Science ®Google Scholar
• RIVM. Volksgezondheid Toekomst Verkenning, Nationaal Kompas Volksgezondheid (National Public Health Compass) version 3.12. Bilthoven: National Institute for Public Health and the Environment; 2007.
   Google Scholar